Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma
Inge Marie Svane
15 participants
Jun 29, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nivolumab 3 mg/kg Ipilimumab 1 mg/kg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07501117